Cardiovascular Considerations During Cancer Therapy
Open Access
- 5 November 2024
- journal article
- research article
- Published by Elsevier in JACC: Cardiooncology
- Vol. 6 (6) , 815-834
Abstract
No abstract availableKeywords
This publication has 118 references indexed in Scilit:
- Atorvastatin for Anthracycline-Associated Cardiac DysfunctionJAMA, 2023
- Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019JAMA Oncology, 2021
- Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta‐analysisEuropean Journal of Heart Failure, 2021
- Assessment and Management of Cardiovascular Risk Factors Among US Veterans With Prostate CancerJAMA Network Open, 2021
- R‐COMP versus R‐CHOP as first‐line therapy for diffuse large B‐cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO groupCancer Medicine, 2021
- Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitorsInternational Journal of Cancer, 2020
- Cardiotoxicity and Myocardial Hypoperfusion Associated with Anti-Vascular Endothelial Growth Factor Therapies: Prospective Cardiac Magnetic Resonance Imaging in Patients with CancerEuropean Journal of Heart Failure, 2020
- Troponins and Brain Natriuretic Peptides for the Prediction of Cardiotoxicity in Cancer Patients: A Meta-AnalysisEuropean Journal of Heart Failure, 2019
- Management of radiotherapy patients with implanted cardiac pacemakers and defibrillators: A Report of the AAPM TG‐203†Medical Physics, 2019
- Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall SurvivalJAMA Oncology, 2016